Hal Hirte

417 total citations
11 papers, 333 citations indexed

About

Hal Hirte is a scholar working on Reproductive Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hal Hirte has authored 11 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Reproductive Medicine, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Hal Hirte's work include Ovarian cancer diagnosis and treatment (7 papers), Angiogenesis and VEGF in Cancer (2 papers) and Intraperitoneal and Appendiceal Malignancies (2 papers). Hal Hirte is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Angiogenesis and VEGF in Cancer (2 papers) and Intraperitoneal and Appendiceal Malignancies (2 papers). Hal Hirte collaborates with scholars based in Canada, United States and Netherlands. Hal Hirte's co-authors include Sébastien J. Hotte, Laurie Elit, J. David Knox, Dongsheng Tu, Lillian L. Siu, Martin Gleave, Wendy Walsh, Elizabeth A. Eisenhauer, Kim N. and Jean Powers and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Hal Hirte

10 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hal Hirte Canada 8 155 149 89 51 49 11 333
Manuela Puopolo Italy 9 272 1.8× 164 1.1× 98 1.1× 120 2.4× 45 0.9× 11 521
Terrence J. Colgan Canada 6 147 0.9× 93 0.6× 65 0.7× 28 0.5× 25 0.5× 8 339
Luisa Carrara Italy 11 95 0.6× 167 1.1× 126 1.4× 26 0.5× 32 0.7× 11 374
Jeffrey C. Goh Australia 11 109 0.7× 167 1.1× 167 1.9× 39 0.8× 51 1.0× 35 376
Mojca Persic United Kingdom 6 103 0.7× 147 1.0× 167 1.9× 31 0.6× 93 1.9× 12 345
Josep M. del Campo Spain 10 131 0.8× 187 1.3× 261 2.9× 51 1.0× 89 1.8× 20 439
Betül T. Yesilyurt Belgium 8 184 1.2× 194 1.3× 79 0.9× 140 2.7× 71 1.4× 9 452
Karin Tyburski United States 6 230 1.5× 291 2.0× 282 3.2× 33 0.6× 99 2.0× 9 510
Nathalie L.G. Sieben Netherlands 8 195 1.3× 108 0.7× 193 2.2× 131 2.6× 108 2.2× 8 433
Eirini Thanopoulou United Kingdom 12 121 0.8× 148 1.0× 27 0.3× 113 2.2× 28 0.6× 26 401

Countries citing papers authored by Hal Hirte

Since Specialization
Citations

This map shows the geographic impact of Hal Hirte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal Hirte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal Hirte more than expected).

Fields of papers citing papers by Hal Hirte

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hal Hirte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal Hirte. The network helps show where Hal Hirte may publish in the future.

Co-authorship network of co-authors of Hal Hirte

This figure shows the co-authorship network connecting the top 25 collaborators of Hal Hirte. A scholar is included among the top collaborators of Hal Hirte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hal Hirte. Hal Hirte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Vergote, Ignace, et al.. (2009). Aflibercept (VEGF TRAP) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: results of a randomized, double-blind, placebo-controlled study. 7 indexed citations
2.
N., Kim, Lillian L. Siu, Hal Hirte, et al.. (2008). A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research. 14(3). 833–839. 95 indexed citations
3.
4.
5.
Hirte, Hal, Amit M. Oza, Paul Hoskins, et al.. (2003). 159 Phase II study of OSI-774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC ctg Ind.149. European Journal of Cancer Supplements. 1(5). S51–S51. 1 indexed citations
6.
Elit, Laurie & Hal Hirte. (2002). Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Current Opinion in Obstetrics & Gynecology. 14(1). 67–73. 41 indexed citations
7.
Hotte, Sébastien J. & Hal Hirte. (2002). BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies. Current Pharmaceutical Design. 8(25). 2249–2253. 86 indexed citations
8.
Hirte, Hal, Ignace Vergote, Gavin Stuart, et al.. (2001). An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT). 20. 15 indexed citations
9.
Rusthoven, James J., E. Eisenhauer, J. Mazurka, et al.. (1993). Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma. JNCI Journal of the National Cancer Institute. 85(10). 823–825. 11 indexed citations
10.
Rusthoven, James J., Leslie Levin, J. Mazurka, et al.. (1991). Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor. JNCI Journal of the National Cancer Institute. 83(23). 1748–1753. 23 indexed citations
11.
Rusthoven, James J., L Levin, E. Eisenhauer, et al.. (1991). A phase I study of GM-CSF, cyclophosphamide (CP), and escalating doses of carboplatin (CBDCA) in chemotherapy-Naïve patients with ovarian cancer. Gynecologic Oncology. 40(2). 169–170. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuela Puopolo Breakdown of academic impact, for papers by Terrence J. Colgan Breakdown of academic impact, for papers by Luisa Carrara Breakdown of academic impact, for papers by Jeffrey C. Goh Breakdown of academic impact, for papers by Mojca Persic Breakdown of academic impact, for papers by Josep M. del Campo Breakdown of academic impact, for papers by Betül T. Yesilyurt Breakdown of academic impact, for papers by Karin Tyburski Breakdown of academic impact, for papers by Nathalie L.G. Sieben Breakdown of academic impact, for papers by Eirini Thanopoulou
Rankless by CCL
2026